Elevated sympathetic nerve activity in patients with accelerated essential hypertension.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 1 of the 16 sources its claims cite were checked for support.
Abstract
To determine if an abnormality exists in the sympathetic nervous system of patients with accelerated hypertension, we recorded muscle sympathetic nerve activity (MSNA) from the tibial nerve by microneurography in eight benign essential hypertensives and seven accelerated essential hypertensives. Basal MSNA, plasma renin activity, and plasma angiotensin II levels were significantly higher in accelerated hypertensives than in benign hypertensives (P < 0.05). To clarify the relationship between the renin-angiotensin axis and sympathetic nervous system in the accelerated hypertensives, we measured the MSNA after 7 d of oral administration of captopril (75 mg/d) for antihypertensive treatment in the benign hypertensives and accelerated hypertensives. After administering captopril, the arterial pressure decreased significantly in the benign hypertensives and accelerated hypertensives with decreases in plasma angiotensin II levels, and the decreases in arterial pressure were greater in the accelerated hypertensive than in the benign hypertensives. After captopril administration, the MSNA decreased significantly in the accelerated hypertensives but did not change in the benign hypertensives. Thus, in accelerated hypertensives, sympathetic tone is elevated, and the elevated sympathetic tone is closely related to the activated renin-angiotensin axis tone.
Overview
CoChat Summary
TL;DR
In accelerated essential hypertensives, basal muscle sympathetic nerve activity (MSNA), plasma renin activity, and plasma angiotensin II were significantly higher than in benign hypertensives. Captopril lowered blood pressure and angiotensin II in both groups but reduced MSNA only in accelerated hypertensives, suggesting elevated sympathetic tone is linked to renin-angiotensin axis activation.
Key findings
Basal MSNA was significantly higher in accelerated hypertensives than in benign hypertensives (P < 0.05).
- Basal plasma renin activity was 6.5±1.0 vs 1.4±0.3 ng ANG I·ml⁻¹·h⁻¹, and plasma angiotensin II was 59±5 vs 19±4 pg·ml⁻¹ in accelerated vs benign hypertensives (P < 0.05).
- Resting arterial pressure was higher in accelerated hypertensives: systolic 210±3 vs 161±4 mmHg and diastolic 126±3 vs 91±2 mmHg (P < 0.05).
- After 7 d of captopril (75 mg/d), plasma angiotensin II decreased significantly in both groups, arterial pressure decreased significantly in both groups, and the depressor response was greater in accelerated hypertensives. MSNA decreased significantly in accelerated hypertensives but did not change significantly in benign hypertensives.
Methods
Single-blind trial of placebo and captopril in eight benign essential hypertensives (four males, four females; 40±3 yr) and seven accelerated essential hypertensives (four males, three females; 39±2 yr).
- MSNA was recorded from the tibial nerve by microneurography; basal values were measured after 30 min supine rest, and captopril was then given orally for 7 d (75 mg/d).
- Plasma renin activity and plasma angiotensin II were measured by radioimmunoassay; arterial pressure, heart rate, and MSNA were compared using paired and unpaired Student’s t tests, with significance at P < 0.05.
- Captopril measurements were repeated in eight benign hypertensives and five of seven accelerated hypertensives.
Limitations
The paper does not state a formal limitations section.
- Evident from the text: the sample was small (8 benign and 7 accelerated hypertensives), and captopril follow-up included only 5 of 7 accelerated hypertensives.
- Evident from the text: there was no normotensive control group, treatment was short-term (7 d), and the design cannot establish causality between renin-angiotensin activation and elevated MSNA.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 5 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The activation of the renin-angiotensin axis is known to play a very important role in the pathogenesis and pathophysiology of accelerated or malignant hypertension (7, 8).”
- Also stated in: § Discussion · p. 3 · boosted
“The activation of renin-angiotensin axis is known to play a very important role in the pathogenesis of accelerated or malignant hypertension (7, 8).”
What the sources say
- Partly supportedcites [7] 7. Laragh, J. H., S. Ulick, W. Januszewicz, Q. B. Deming, W. G. Kelly, and S. Lieberman. 1960. Aldosterone secretion and primary and malignant hypertension. J. Clin. Invest. 39:1091-1106. sourceExperimental — accuracy not yet measured
The Summary reports elevated aldosterone secretion in 14 of 15 patients with malignant hypertension, supporting an association with the condition. The Discussion says aldosterone might contribute to the malignant syndrome but could also be a consequence of it. The paper does not establish activation of the renin–angiotensin axis or its important causal role (searched: renin, angiotensin, and pathogenesis). (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [8] 8. Rosset, E., J. R. Scherrer, and R. Veyrat. 1973. Increased plasma renin substrate concentration in human malignant hypertension. Helv. Med. Acta. 37:235-250.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MSNA decreased significantly in accelerated hypertensives, but did not change significantly in benign hypertensives (Fig. 2).”
- Also stated in: § Abstract · p. 1 · plain
“After captopril administration, the MSNA decreased significantly in the accelerated hypertensives but did not change in the benign hypertensives.”
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MSNA decreased significantly in accelerated hypertensives, but did not change significantly in benign hypertensives (Fig. 2).”
- Also stated in: § Abstract · p. 1 · plain
“After captopril administration, the MSNA decreased significantly in the accelerated hypertensives but did not change in the benign hypertensives.”
plainstates a causen = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Basal MSNA, plasma renin activity, and plasma angiotensin II levels were significantly higher in accelerated hypertensives than in benign hypertensives (P < 0.05).”
- Also stated in: § Results · p. 2 · plain
“The basal MSNA was significantly higher in the accelerated hypertensives than in the benign hypertensives (P < 0.05, Fig. 1).”
- Also stated in: § Discussion · p. 3 · plain
“The basal MSNA was greater in the accelerated hypertensives than in the benign hypertensives.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · p. 2 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The heart rate in the accelerated hypertensives did not differ from that in benign hypertensives (Table I).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 24 claims and to verify the 3 references still open.
- The quote only partly states this claim. 3
- Probably not a substantial claim. 3
- It may state two separate claims as one. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, the increased activity in EHT + LVH was not attributable to antihypertensive treatment and, in fact, was still apparent despite the use of agents”
From Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive (2001) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Also, treatment with angiotensin-converting enzyme inhibitors in hypertension has been shown to have either no effect or decrease sympathetic nerve traffic (31,32).”
From Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive (2001) · cites this paper as [32]
Citations
Cites
Anderson, E. A., Sinkey, C. A., Lawton, W. J., & Mark, A. L. (1989) · Hypertension · doi:10.1161/01.hyp.14.2.177 · Cited by 632
Evidence for a Central Mechanism in Angiotensin Induced Hypertension.
Bickerton, R. K., & Buckley, J. P. (1961) · Experimental Biology and Medicine · doi:10.3181/00379727-106-26492 · Cited by 387
Cardiovascular Effects of Angiotensin Mediated by the Central Nervous System
FERRARIO, C. M., GILDENBERG, P. L., & MCCUBBIN, J. W. (1972) · Circulation Research · doi:10.1161/01.res.30.3.257 · Cited by 353
ALDOSTERONE SECRETION AND PRIMARY AND MALIGNANT HYPERTENSION *
Laragh, J. H., Ulick, S., Januszewicz, V., Deming, Q. B., Kelly, W. G., & Lieberman, S. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104124 · Cited by 305
Adrenergic Facilitation by Angiotensin: Does it Serve a Physiological Function?
Zimmerman, B. G. (1981) · Clinical Science · doi:10.1042/cs0600343 · Cited by 255 · cited 1×
“tensin II (ANG II) is known to stimulate the sympathetic nervous system at the level of the adrenergic nerve ending (9, 10),”
BackgroundAge-related changes in muscle sympathetic nerve activity in essential hypertension
Yamada, Y., Miyajima, E., Tochikubo, O., Matsukawa, T., & Ishii, M. (1989) · Hypertension · doi:10.1161/01.hyp.13.6.870 · Cited by 220
Self-citationEvidence that angiotensin enhances transmitter release during sympathetic nerve stimulation
HUGHES, J., & ROTH, R. H. (1971) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1971.tb08025.x · Cited by 197
The action of angiotensin and bradykinin on the superior cervical ganglion of the cat.
Lewis, G. P., & Reit, E. (1965) · The Journal of Physiology · doi:10.1113/jphysiol.1965.sp007679 · Cited by 187
Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans
Matsukawa, T., Gotoh, E., Minamisawa, K., Kihara, M., Ueda, S., Shionoiri, H., & Ishii, M. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.261.3.r690 · Cited by 113
Self-citationAugmented sympathetic nerve activity in response to stressors in young borderline hypertensive men
MATSUKAWA, T., GOTOH, E., UNEDA, S., MIYAJIMA, E., SHIONOIRI, H., TOCHIKUBO, O., & ISHII, M. (1991) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1991.tb09064.x · Cited by 97
Self-citation
Research works printed but not linked: 1
- [17]17. Wallin, B. G. 1983. Intraneural recording and autonomic function in man. In Autonomic Failure. R. Bannister, editor. Oxford University Press, London. pp. 36–51.
Cited by
Pescatello, L. S., Franklin, B. A., Fagard, R., Farquhar, W. B., Kelley, G. A., & Ray, C. A. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000115224.88514.3a · Cited by 1,872
“Muscle SNA was elevated in hypertensive subjects as compared with normotensive subjects in some (82,99,174,175) but not all studies (183,269).”
ResultHow to assess sympathetic activity in humans
Grassi, G., & Esler, M. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917060-00001 · Cited by 455
Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure
Ligtenberg, G., Blankestijn, P. J., Oey, P. L., Klein, I. H. H., Dijkhorst-Oei, L.-T., Boomsma, F., Wieneke, G. H., van Huffelen, A. C., & Koomans, H. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401704 · Cited by 409
Hermann, M., Flammer, A., & Lüscher, T. F. (2006) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06032.x · Cited by 354
Blood flow restriction training and the exercise pressor reflex: a call for concern
Spranger, M. D., Krishnan, A. C., Levy, P. D., O'Leary, D. S., & Smith, S. A. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00208.2015 · Cited by 293
Role of the sympathetic nervous system in human hypertension
Grassi, G. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816121-00019 · Cited by 289
“…et al. (1983), Wallin et al. (1984) [55,56] Increase Reduction Calcium antagonists Calhoun (1998) [57] Increase Increase Angiotensin converting Matsukawa et al. (1993), enzyme inhibitors Grassi et al. (1998) [58,59] Unknown No change Angiotensin II receptor Ashino et al. (1994) [60] Unknown…”
BackgroundSympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call
Koomans, H. A., Blankestijn, P. J., & Joles, J. A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000113320.57127.b9 · Cited by 205
“Increased MSNA has also been found in many other types of hypertension: renovascular hypertension (25), malignant hypertension (26), pre-eclampsia (27), and hypertension associated with obesity (28), and hypercapnia (29).”
The Hypothalamus and Hypertension
De Wardener, H. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1599 · Cited by 205
Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects
Matsukawa, T., Sugiyama, Y., Watanabe, T., Kobayashi, F., & Mano, T. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.275.5.r1600 · Cited by 183
Self-citationSingle-Unit Sympathetic Discharge: Quantitative Assessment in Human Hypertensive Disease
Greenwood, J. P., Stoker, J. B., & Mary, D. A. S. G. (1999) · Circulation · doi:10.1161/01.cir.100.12.1305 · Cited by 174
Role of nitric oxide in the neural control of cardiovascular function
Zanzinger, J. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00085-1 · Cited by 174
Increased Sympathetic Nerve Activity in Renovascular Hypertension
Johansson, M., Elam, M., Rundqvist, B., Eisenhofer, G., Herlitz, H., Lambert, G., & Friberg, P. (1999) · Circulation · doi:10.1161/01.cir.99.19.2537 · Cited by 172
Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive
Greenwood, J. P., Scott, E. M., Stoker, J. B., & Mary, D. A. S. G. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01600-x · Cited by 161
Redox Control of Renal Function and Hypertension
Nistala, R., Whaley-Connell, A., & Sowers, J. R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2034 · Cited by 146
“An extensive body of literature links the sympathetic nervous system (SNS) and hypertension (2, 191, 205, 279, 285).”
Grassi, G. M., Pisano, A., Bolignano, D., Seravalle, G., D’Arrigo, G., Quarti‐Trevano, F., Mallamaci, F., Zoccali, C., & Mancia, G. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11038 · Cited by 152
“Thirteen studies reported MSNA expressed as burst incidence over time or as burst incidence corrected for HR only.(3,5,8,15,16,18,33,38,40,41,46,49,51) MSNA was recorded in the peroneal nerve of supine or semisupine subjects in 34 studies, whereas in the remaining 6 studies, MSNA was recorded in the tibial nerve.”
BackgroundInfluentialDudenbostel, T., Acelajado, M. C., Pisoni, R., Li, P., Oparil, S., & Calhoun, D. A. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05449 · Cited by 135
“之前的研究已经明确,交感神经活性(sympathetic nerve activity,SNA)增高与动脉高血压的发生发展及维 持密切相关([25])。交感神经系统活性进行性增高,与高血压 严重程度同步发展([26-30])。对于RHTN患者,肾神经导管射 频消融治疗可以降低血压,同时伴随着肌肉SNA下降,后 者由显微神经检查法测定([31-33])。本研究的发现为这些文献”
Time Course of Sympathetic Neural Hyperactivity After Uncomplicated Acute Myocardial Infarction
Graham, L., Smith, P. A., Stoker, J. B., Mackintosh, A., & Mary, D. (2002) · Circulation · doi:10.1161/01.cir.0000025610.14665.21 · Cited by 141
Sakata, K., Shirotani, M., Yoshida, H., Nawada, R., Obayashi, K., Togi, K., & Miho, N. (1999) · Hypertension · doi:10.1161/01.hyp.33.6.1447 · Cited by 114
Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly
Grassi, G., Seravalle, G., Bertinieri, G., Turri, C., DellʼOro, R., Stella, M. L., & Mancia, G. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018050-00012 · Cited by 99
Matsukawa, T., Sugiyama, Y., & Mano, T. (1996) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(96)00057-4 · Cited by 81
Self-citationMizuno, M., Murphy, M. N., Mitchell, J. H., & Smith, S. A. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01145.2010 · Cited by 77
“This is a significant finding when one considers that basal SNA is commonly elevated in hypertension (1, 33, 54) and is associated with the progression of end organ damage (e.”
Sander, M., Hansen, J., & Victor, R. G. (1997) · Hypertension · doi:10.1161/01.hyp.30.1.64 · Cited by 84
Sympathomodulatory Effects of Antihypertensive Drug Treatment
Grassi, G. M. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw012 · Cited by 70
Morabito, M., Crisci, A., Orlandini, S., Maracchi, G., Gensini, G. F., & Modesti, P. A. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.177 · Cited by 66
Graham, L., SMITH, P. A., Stoker, J. B., Mackintosh, A., & Mary, D. (2004) · Clinical Science · doi:10.1042/cs20030376 · Cited by 67
Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension
Binggeli, C., Corti, R., Sudano, I., Lüscher, T. F., & Noll, G. (2002) · Hypertension · doi:10.1161/01.hyp.0000013264.41234.24 · Cited by 57
Hypotensive Response to Losartan in Normal Rats
Collister, J. P., Hornfeldt, B. J., & Osborn, J. W. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.598 · Cited by 55
Baroreflex control of muscle sympathetic nerve activity is attenuated in the elderly
Matsukawa, T., Sugiyama, Y., Watanabe, T., Kobayashi, F., & Mano, T. (1998) · Journal of the Autonomic Nervous System · doi:10.1016/s0165-1838(98)00128-3 · Cited by 51
Self-citationAntihypertensive Drugs and the Sympathetic Nervous System
Colle, S. D., Morello, F., Rabbia, F., Milan, A., Naso, D., Puglisi, E., Mulatero, P., & Veglio, F. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318135446c · Cited by 57
“Nevertheless, the net effects of ACEIs on sympathetic function at the peripheral level tend to ease out during longterm treatment.(120,122,124) In clinical conditions where significantly higher AngII levels are found, such as congestive heart failure(125) and accelerated hypertension,(122) ACEI treatment is accompanie…”
BackgroundIncreased cardiac sympathetic drive in renovascular hypertension
Petersson, M., Rundqvist, B., Johansson, M., Eisenhofer, G., Lambert, G. W., Herlitz, H., Jensen, G., & Friberg, P. (2002) · Journal of Hypertension · doi:10.1097/00004872-200206000-00031 · Cited by 58
Iwase, S., Matsukawa, T., Ishihara, S., et al. (1995) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(95)00022-p · Cited by 43
Self-citationNakata, A., Takata, S., Yuasa, T., Shimakura, A., Maruyama, M., Nagai, H., Sakagami, S., & KOBAYASHI, K. P. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.4.h1211 · Cited by 51
Antihypertensive Drugs and the Sympathetic Nervous System
Wenzel, R. R., Bruck, H., Noll, G., fers, R. F. S., Daul, A., & Philipp, T. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200000004-00006 · Cited by 43
Obstructive sleep apnea as a cause of neurogenic hypertension
Narkiewicz, K., & Somers, V. K. (1999) · Current Hypertension Reports · doi:10.1007/s11906-999-0032-7 · Cited by 42
Interactive Effect of Heart Rate and Muscle Sympathetic Nerve Activity on Blood Pressure
Narkiewicz, K., & Somers, V. K. (1999) · Circulation · doi:10.1161/01.cir.100.25.2514 · Cited by 43
Aileru, A. A., Albuquerque, A. D., Hamlyn, J. M., Manunta, P., Shah, J. R., Hamilton, M. J., & Weinreich, D. M. (2001) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2001.281.2.r635 · Cited by 38
“INCREASED SYMPATHETIC NERVE ACTIVITY (SNA) has been implicated in the development and maintenance of several forms of human and experimental hypertension (2, 8, 13, 18, 24, 26, 34, 35, 38, 43).”
芦野, 和., Gotoh, E., Sumita, S., Moriya, A., & Ishii, M. (1997) · Circulation · doi:10.1161/01.cir.96.10.3443 · Cited by 40
Self-citationFan, X.-H., Wang, Y.-B., Wang, H., Sun, K., Zhang, W.-L., Song, X.-D., Cheng, J.-Z., Wu, H.-Y., Zhou, X.-L., & Hui, R. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.110 · Cited by 38
Oxidized LDL and lipoprotein(a) stimulate renin release of juxtaglomerular cells
Galle, J., Stunz, P., Schollmeyer, P. J., & Wanner, C. (1995) · Kidney International · doi:10.1038/ki.1995.5 · Cited by 35
Cleophas, T. J., & van Marum, R. J. (2003) · Drugs & Aging · doi:10.2165/00002512-200320050-00001 · Cited by 32
Yang, Y., Lin, H., Huang, Y., Lee, T.-Y., Hou, M., Lee, F., Liu, R.-S., Chang, F.-Y., & Lee, S. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00037-5 · Cited by 32
Neural mechanisms in nitric-oxide-deficient hypertension
Sander, M., & Victor, R. G. (1999) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199901000-00011 · Cited by 29
Neural and Hypotensive Effects of Angiotensin II Receptor Blockade
Rongen, G. A. P. J. M., Brooks, S. C., Ando, S., Dajani, H. R., Abramson, B. L., & Floras, J. S. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.378 · Cited by 31
Allen, A. M. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.12.003 · Cited by 25
A new method of quantifying human muscle sympathetic nerve activity for frequency domain analysis
Sugiyama, Y., Matsukawa, T., Suzuki, H., Iwase, S., Shamsuzzaman, A., & Mano, T. (1996) · Electroencephalography and Clinical Neurophysiology/Electromyography and Motor Control · doi:10.1016/0924-980x(95)00219-b · Cited by 26
Self-citationSpranger, M. D., Kaur, J., Sala‐Mercado, J. A., Krishnan, A. C., Abu‐Hamdah, R., Alvarez, A., Machado, T. M., Augustyniak, R. A., & O’Leary, D. S. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00417.2016 · Cited by 23
“Resting SNA is heightened in hypertension (34, 38, 53, 74, 75, 78, 114).”
Duarte, C. G., Zhang, J., & Ellis, S. (1997) · Renal Failure · doi:10.3109/08860229709037213 · Cited by 23
Area postrema lesion attenuates the long-term hypotensive effects of losartan in salt-replete rats
Collister, J. P., & Osborn, J. W. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.2.r357 · Cited by 26
“Blockade of the RAS is also useful in treating forms of hypertension in which renin levels are not elevated, socalled non-renin-dependent types of hypertension (8, 47, 61).”
BackgroundLong-term blood pressure control: is there a set-point in the brain?
Nishida, Y., Tandai-Hiruma, M., Kemuriyama, T., & Hagisawa, K. (2012) · The Journal of Physiological Sciences · doi:10.1007/s12576-012-0192-0 · Cited by 20
Aileru, A. A., Logan, E., Callahan, M., Ferrario, C. M., Ganten, D., & Diz, D. I. (2004) · Hypertension · doi:10.1161/01.hyp.0000112422.81661.f3 · Cited by 19
Neuroadrenergic disarray in pseudo-resistant and resistant hypertension
Grassi, G. M., Bombelli, M., Buzzi, S., Volpe, M., & Brambilla, G. (2014) · Hypertension Research · doi:10.1038/hr.2014.25 · Cited by 18
ANTIHYPERTENSIVE DRUGS AND SYMPATHETIC NERVOUS SYSTEM
Rabbia, F., Martini, G., Genova, G. C., Milan, A., Chiandussi, L., & Veglio, F. (2001) · Clinical and Experimental Hypertension · doi:10.1081/ceh-100001201 · Cited by 21
“On the other hand, AII levels are not markedly increased as in congestive heart failure (58) and accelerated hypertension (57), which are clinical conditions where ACE I treatment is accompanied by a significant decrease in MSNA.”
BackgroundSympathetic Neural Control in Humans with Anxiety‐Related Disorders
Bigalke, J. A., & Carter, J. R. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210027 · Cited by 36
“…sympathetic activity increases naturally with age (170, 239), excessive sympathetic activation has also been observed in numerous chronic disease states including hypertension (6, 82, 124, 126, 220, 277), heart failure (128, 200), obesity (122), and obstructive sleep apnea (234–236) among others.”
Weck, M. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0535-7 · Cited by 17
“[65], captopril reduced muscle sympathetic nerve activity.”
β-Adrenergic Receptors and Angiotensinogen Gene Expression in Mouse Hepatoma Cells In Vitro
Ming, M., Wu, J., Lachance, S., Delalandre, A., Carrière, S., & Chan, J. S. D. (1995) · Hypertension · doi:10.1161/01.hyp.25.1.105 · Cited by 17
Zhang, J., Fallahzadeh, M. K., & McCullough, P. A. (2016) · Cardiorenal Medicine · doi:10.1159/000447542 · Cited by 18
Role of Long-Term Potentiation of Sympathetic Ganglia (gLTP) in Hypertension
Alkadhi, K. A., & Alzoubi, K. H. (2007) · Clinical and Experimental Hypertension · doi:10.1080/10641960701500356 · Cited by 17
Failure of Antihypertensive Treatment to Restore Normal Sympathetic Activity
Quarti‐Trevano, F., Seravalle, G., Facchetti, R., Tsioufis, K. P., Dimitriadis, K. S., Manta, E., Mancia, G., & Grassi, G. M. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24429 · Cited by 14
Use of Microneurography to Evaluate Sympathetic Activity in Hypertension: A Brief Review
Yucha, C. B. (2000) · Applied Psychophysiology and Biofeedback · doi:10.1023/a:1009537506603 · Cited by 19
Pagani, M. (2000) · Current Medical Research and Opinion · doi:10.1185/0300799009117032 · Cited by 16
Duarte, C. G., Zhang, J., & ELLIS, A. S. (2001) · Investigative Radiology · doi:10.1097/00004424-200101000-00008 · Cited by 11
Hoffman, R. P., Sinkey, C. A., & Anderson, E. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.3.287 · Cited by 12
Postganglionic Sympathetic Discharge in Neonatal Swine
Sica, A. L., Hundley, B. W., & Gootman, P. M. (1996) · Pediatric Research · doi:10.1203/00006450-199601000-00012 · Cited by 11
Rocha‐Pereira, C., Sousa, J. B., Vieira-Rocha, M. S., et al. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.02.010 · Cited by 10
Minami, N., Imai, Y., Nishiyama, H., & Abe, K. (1997) · Hypertension · doi:10.1161/01.hyp.29.4.969 · Cited by 10
Role of the sympathetic nervous system in human renovascular hypertension
Johansson, M., & Friberg, P. (2000) · Current Hypertension Reports · doi:10.1007/s11906-000-0016-0 · Cited by 11
Matsukawa, T., & Miyamoto, T. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00471.2007 · Cited by 10
“In addition, our previous studies suggested the occurrence of augmented sympathetic nerve activity in both patients with accelerated hypertension (15) and those with renovascular hypertension (18), which showed elevated renin-angiotensin system activity.”
BackgroundSelf-citationJeppesen, T. D., Vissing, J., & González‐Alonso, J. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.11.003 · Cited by 11
Insulin Resistance and Blood Pressure
Ferrannini, E. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-716-1_15 · Cited by 14
Koike, Y., Kawabe, T., Nishihara, K., Iwane, N., & Hano, T. (2015) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1025959 · Cited by 8
“Sympathetic nerve activity (SNA) is stimulated by mental stress, cold, pain (1) and physical stress (2,3), and in line with this, essential hypertension and accelerated hypertension have been shown to accompany sympathetic activation (4,5).”
BackgroundAn Analysis of Medication Prescriptions for Hypertension in Urban and Rural Residents in Tianjin
Zhang, Y., Yang, H., Wang, R., Zhao, F., Liu, T., Zhang, Y., Guo, Z., & Cong, H. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01475-y · Cited by 5
Collister, J. P., & Osborn, J. W. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000167014.84715.6e · Cited by 5
The Phantom in our opera - or the hidden ways of the autonomic nervous system in cardiac patients.
van Tellingen, C. (2004) · PubMed · Cited by 5
Shiba, T., Sugiyama, T., Hori, Y., Matsumoto, T., Maeno, T., & Takahashi, M. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3145-5 · Cited by 4
“In addition, it has been reported that the regulation of blood pressure is strongly associated with reflect sympathetic nerve activity in both human hypertension [22] and spontaneously hypertensive rats [23, 24].”
BackgroundPrimary arterial hypertension in athletes
Sadykova, D. I., & Lutfullin, I. Y. (2012) · Kazan medical journal · doi:10.17816/kmj2108 · Cited by 6
“Существует другое исследование, указывающее, что высокое АД в периоде восстановления после выполненного упражнения является предиктором ЭАГ [20].”
Hypertension and Insulin Resistance
Natali, A., Taddei, S., & Ferrannini, E. (1997) · Humana Press eBooks · doi:10.1007/978-1-4757-3906-0_16 · Cited by 4
Vetha, B. S. S., Byrum, R., Peele, K., Diz, D. I., & Aileru, A. A. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001368 · Cited by 3
Role of Sympathetic Nervous System in Hypertension
Kaul, C. L., & Ramarao, P. (2003) · Progress in experimental cardiology · doi:10.1007/978-1-4419-9232-1_12 · Cited by 2
“Even in accelerated essential and renovascular hypertension increase in the muscle sympathetic nervous activity has been reported [15,19].”
BackgroundAlkadhi, K. A., & Alzoubi, K. H. (2010) · CRC Press eBooks · doi:10.1201/b10317-27 · Cited by 1
Novas Perspectivas no Tratamento da Hipertensão
Lopes, H. F. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201164 · Cited by 4
SANDE, F. M. V. D., Kroon, A. A., Kooman, J. P., & Leunissen, K. M. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4252-5.50186-6 · Cited by 1
Shamsuzzaman, A., & Somers, V. K. (2003) · Elsevier eBooks · doi:10.1016/b0-12-226870-9/00225-2 · Cited by 2
Oneda, B. (2006) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2006.tde-19032010-114027
Oneda, B. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2010.tde-10052010-121050 · Cited by 1
CENTRAL NEURAL MECHANISMS OF SALT-SENSITIVE HYPERTENSION
Larson, R. A. (2016) · Digital Commons - Michigan Tech (Michigan Technological University) · doi:10.37099/mtu.dc.etdr/188
Buttler, L. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2016.tde-09112016-144856 · Cited by 1
Ely, B. R. (2018) · Scholars' Bank (University of Oregon)
Monteiro, W. (2009) · Revista Brasileira de Fisiologia do Exercício · doi:10.33233/rbfe.v4i1.3586 · Cited by 1
Muscle Metaboreflex Control Of Cardiovascular Function In Hypertension
Spranger, M. D. (2014) · Human Biology
Leunissen, K. M. L., & Kooman, J. P. (1998) · Springer eBooks · doi:10.1007/978-94-011-5482-6_85 · Cited by 1
Pathophysiological basis of hypertension
Distler, A., & Sharma, A. M. (1996) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-1647-0_4
Stimulus response coupling in the carotid body: a role for metabolic signalling
Holmes, A. P. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Moreira, J. D. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00147.2026
Metadata
- Authors
- Matsukawa, T., Mano, T., Gotoh, E., & Ishii, M.
- Affiliations
- Nagoya University (JP)
- Research Institute of Environmental Medicine, Nagoya University (JP)
- Yokohama City University (JP)
- ORCID
- Ishii, M
- Venue
- Journal of Clinical Investigation
- Published
- 1993-07-01
- Volume
- 92
- Issue
- 1
- Pages
- 25-28
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC293521
- OpenAlex
- W2023629143
- Cited by
- 94
- References
- 19
- Citations by year
- 2026: 1 · 2025: 1 · 2022: 1 · 2021: 3 · 2020: 1 · 2018: 2 · 2016: 5 · 2015: 4 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- muscle sympathetic nerve activity, sympathetic nervous system, renin-angiotensin system, plasma renin activity, plasma angiotensin II, captopril, antihypertensive therapy, arterial pressure, tibial nerve
- MeSH terms
- Adult, Angiotensin II, Blood Pressure, Captopril, Female, Heart Rate, Humans, Hypertension, Male, Renin, Sympathetic Nervous System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

